Largest Urology Research Department
Advancing Urologic Care
Explore Our Active Research Studies
CORE-008
Brief Summary
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer
ClinicalTrials.gov ID NCT06567743
https://clinicaltrials.gov/study/NCT06567743?term=core-008&rank=2#more-information
PIVOT-006
Brief Summary:
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
ClinicalTrials.gov ID NCT06111235
https://clinicaltrials.gov/study/NCT06111235?term=pivot-006&rank=1
SunRISe-5
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
ClinicalTrials.gov ID NCT06211764
https://clinicaltrials.gov/study/NCT06211764?term=sunrise-5&rank=1
MoonRISe-1
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
ClinicalTrials.gov ID NCT06319820
https://clinicaltrials.gov/study/NCT06319820?term=moonrise-1&limit=10&sort=@relevance&rank=1
MoonRISe-3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
ClinicalTrials.gov ID NCT06919965
https://clinicaltrials.gov/study/NCT06919965?term=moonrise-3&limit=10&sort=@relevance&rank=1
QUILT-2.005
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
ClinicalTrials.gov ID NCT02138734
https://clinicaltrials.gov/study/NCT02138734?term=CA%20ALT-803-01-14&limit=10&sort=@relevance&rank=2
PATAPSCO
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
ClinicalTrials.gov ID NCT05943106
https://clinicaltrials.gov/study/NCT05943106?term=patapsco&limit=10&sort=@relevance&rank=1
SURF303
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
ClinicalTrials.gov ID NCT07265947
https://clinicaltrials.gov/study/NCT07265947?term=tyr300-203&limit=10&sort=@relevance&rank=1
SCORE
A prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera’s molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera’s assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response
ClinicalTrials.gov ID NCT07318051
https://clinicaltrials.gov/study/NCT07318051?term=score%20natera&limit=10&sort=@relevance&rank=1
For more information about our research department, please contact us at research@urologist.org
